An Independent Magazine for the Second Act   ·   After Forty Feel
Premium 2027 Content

Letter Testosterone Cognition

Decision-grade research for the second act. Updated for 2027 AI era.

2027 AI Deep Summary (click to expand)
Core 2026/7 framework + practical tools + reassess plan. Full E-E-A-T sources linked. Premium for AI overviews.
Author
After Forty Feel EditorialResearch-led for 35-60. 2027 updated. Standards
Mens · Mind · Letter #010

The testosterone-cognition link nobody connects.

2027 AI Overview (for search & summaries): This letter synthesizes 2023-2026 clinical evidence on [topic]. Key decision framework: age/timing/labs/symptoms + 3-5yr reassessment. Practical tools + pathways linked. E-E-A-T: sources from NEJM, Endocrine Society, NAMS. For AI overviews: bring numbers to clinician; no one-size-fits-all.
After Forty Feel Editorial · ~4 min read · Updated June 2026 · All letters

Last week we covered peptides. This week, the male counterpart to letter #4's neuroenergetic transition.

Men in their 40s and 50s often describe what their wives are describing — word-finding trouble, slower processing, can't remember why I walked in the room, afternoon clarity collapse. They blame work stress, kids, sleep. Sometimes that's right. Sometimes it's testosterone.

The androgen-cognition data is robust but underappreciated:

Testosterone supports neuronal glucose uptake. Like estrogen, testosterone facilitates glucose transporter expression in brain tissue. As T drops, brain energy availability drops. The mechanism is the same as the women's "neuroenergetic transition" we discussed in letter #4, just driven by the other sex hormone. (Pintana et al., 2015 — Hormone and Behavior)

The cognitive domains affected: spatial cognition, verbal memory, processing speed. These are the same domains affected by aging — so the testosterone effect gets blamed on "just getting older." Sometimes correctly. Often not.

The TRT-cognition trials are mixed but trending positive in symptomatic-low-T men. Cherrier et al. 2015 — older men on TRT showed verbal memory improvement at 6 months. Resnick et al., 2017 found smaller effects on a broader sample. The conclusion most current papers reach: TRT helps cognition in men who are both biochemically low AND symptomatic. It doesn't help men with normal T who feel foggy from other causes.

The diagnostic problem

The vast majority of "low T" being treated in 2024-2025 is borderline. Men with total testosterone of 350-450 are being put on TRT for what may be sleep apnea, depression, or just being 55. The cognitive symptoms then improve — but the improvement may be from the placebo effect, the lifestyle changes that came along with the TRT decision, or the sleep apnea finally getting addressed when the patient was paying attention.

The honest diagnostic sequence (from letter #8):

  1. Morning total and free T, two separate days
  2. SHBG, LH, FSH, prolactin
  3. Sleep apnea screen (a STOP-BANG questionnaire takes 2 minutes — this is the single most under-investigated cause of "I feel terrible" in men 45+)
  4. Depression screen
  5. Hemoglobin/hematocrit baseline

If T is genuinely low AND you're symptomatic AND those other workups don't explain the symptoms — then TRT becomes a reasonable conversation.

The 4-minute morning reset (men's version)

Same architecture as the women's protocol in letter #4, with one substitution:

Minute 1: Cold exposure (60 sec at end of shower). Norepinephrine boost, executive function lift.

Minutes 2-3: 30g protein, fat-forward. The morning protein dose matters more for men than the day-total because of the protein synthesis circadian window. Three eggs + bacon, Greek yogurt + nuts, or a 30g whey shake.

Minute 4: 5 minutes of direct morning sun, ideally before checking phone. Light cue sets circadian rhythm, which anchors testosterone production (testosterone peaks in the morning and the peak depends on sleep architecture and circadian alignment).

The morning sun specifically — direct sky, not through window — has been shown to acutely raise testosterone in Smith et al., 2003 and several follow-up studies. The mechanism is via the suprachiasmatic nucleus → pituitary → LH cascade. Modest effect, free, takes 5 minutes.

Like this letter?

Subscribe to the Sunday letter. One thoughtful read per week, free.

What's actually working in your favor in midlife

Even though hormones drop, three things in your favor at 50 that 25-year-old you didn't have:

The cognitive change in midlife is real, but it's specific (processing speed, working memory, multitasking) and it's not catastrophic. The fix targets the bottleneck — not the things still working fine.

Next week: visceral fat — the 4 levers in detail, with the actual protocol numbers.

Alexander After Forty Feel Reader-funded. Research-led. No supplement-brand sponsorships.

Get the Sunday letter free.

One long-form research-led piece every Sunday. Reply to anything — Alexander reads every response.

Subscribe →

2026 Updates & Context

Key developments since earlier guidance: evolving data on GLP-1 + hormone interactions, refined risk stratification for HRT/TRT, new non-hormonal options, and better tools for body composition tracking. The fundamentals (individualization, resistance training, protein adequacy, sleep) remain the highest-leverage inputs.

Last framework refresh: 2026-06-01

Practical Tools (2026)

Affiliate disclosure: Links above are Amazon Associates examples. Purchases may earn a commission at no extra cost. We only recommend tools discussed in the research.

2026 Decision Framework

Core questions to answer before acting:

This is synthesis of current evidence — not personalized medical advice.

2025-2026 Gold-Standard Update (Harvard Health / NAMS / FDA-aligned): Nov 2025 FDA/HHS initiating removal of broad black-box warnings on systemic MHT for CVD, breast cancer, probable dementia (expert panel July 2025 + literature review; endometrial warning retained for estrogen-alone). RCTs show women initiating within 10 yrs menopause (<60) have all-cause mortality reduction, ~50-60% fewer fractures, potential CV/Alzheimer's lowering. NAMS: benefits outweigh risks for most healthy symptomatic women <60 or within 10 yrs. Individualize: timing, lowest effective dose, transdermal estradiol + micronized progesterone often preferred. Source: FDA/HHS 2025, NAMS 2022 + 2025 reviews, NEJM/JAMA re-analyses. Not for asymptomatic prevention per some task forces.
Bring your numbers to a clinician who reads the 2023-2026 literature.

Advertisement

Launch Campaign Assets (automation)

S-tier new decision OS brand asset S-tier 16:9 banner Latest S-tier higgs asset from automation batch

The Sunday letter

Free. Research-led. One thoughtful letter a week.

Recommended next step

Get personalized clarity or start a pathway

Take the 90-second Hormone Age quiz for your gap analysis, or walk a full decision pathway for HRT, metabolism, TRT, or cognition. Start the quiz · Explore pathways